These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21207957)

  • 1. Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.
    Baqi Y; Hausmann R; Rosefort C; Rettinger J; Schmalzing G; Müller CE
    J Med Chem; 2011 Feb; 54(3):817-30. PubMed ID: 21207957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective potentiation of homomeric P2X2 ionotropic ATP receptors by a fast non-genomic action of progesterone.
    De Roo M; Boué-Grabot E; Schlichter R
    Neuropharmacology; 2010 Mar; 58(3):569-77. PubMed ID: 20004677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexible subunit stoichiometry of functional human P2X2/3 heteromeric receptors.
    Kowalski M; Hausmann R; Schmid J; Dopychai A; Stephan G; Tang Y; Schmalzing G; Illes P; Rubini P
    Neuropharmacology; 2015 Dec; 99():115-30. PubMed ID: 26184350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.
    Baqi Y; Atzler K; Köse M; Glänzel M; Müller CE
    J Med Chem; 2009 Jun; 52(12):3784-93. PubMed ID: 19463000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P2X1 and P2X2 receptors in the central nervous system as possible drug targets.
    Hausmann R; Schmalzing G
    CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):675-86. PubMed ID: 22963438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
    Kim YC; Brown SG; Harden TK; Boyer JL; Dubyak G; King BF; Burnstock G; Jacobson KA
    J Med Chem; 2001 Feb; 44(3):340-9. PubMed ID: 11462975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors.
    Obrecht AS; Urban N; Schaefer M; Röse A; Kless A; Meents JE; Lampert A; Abdelrahman A; Müller CE; Schmalzing G; Hausmann R
    Neuropharmacology; 2019 Nov; 158():107749. PubMed ID: 31461640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithocholic acid inhibits P2X2 and potentiates P2X4 receptor channel gating.
    Sivcev S; Slavikova B; Ivetic M; Knezu M; Kudova E; Zemkova H
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105725. PubMed ID: 32652201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold.
    Baqi Y; Lee SY; Iqbal J; Ripphausen P; Lehr A; Scheiff AB; Zimmermann H; Bajorath J; Müller CE
    J Med Chem; 2010 Mar; 53(5):2076-86. PubMed ID: 20146483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of selective antagonism of the P2X1 receptor for ATP by NF449 and suramin: contribution of basic amino acids in the cysteine-rich loop.
    El-Ajouz S; Ray D; Allsopp RC; Evans RJ
    Br J Pharmacol; 2012 Jan; 165(2):390-400. PubMed ID: 21671897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor.
    Hoffmann K; Baqi Y; Morena MS; Glänzel M; Müller CE; von Kügelgen I
    J Pharmacol Exp Ther; 2009 Nov; 331(2):648-55. PubMed ID: 19690189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Potent and Selective Antagonists for the UTP-Activated P2Y
    Rafehi M; Malik EM; Neumann A; Abdelrahman A; Hanck T; Namasivayam V; Müller CE; Baqi Y
    J Med Chem; 2017 Apr; 60(7):3020-3038. PubMed ID: 28306255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors.
    Virginio C; Robertson G; Surprenant A; North RA
    Mol Pharmacol; 1998 Jun; 53(6):969-73. PubMed ID: 9614197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salt bridge switching from Arg290/Glu167 to Arg290/ATP promotes the closed-to-open transition of the P2X2 receptor.
    Hausmann R; Günther J; Kless A; Kuhlmann D; Kassack MU; Bahrenberg G; Markwardt F; Schmalzing G
    Mol Pharmacol; 2013 Jan; 83(1):73-84. PubMed ID: 23041661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heteromeric channels with different phenotypes are generated when coexpressing two P2X2 receptor isoforms.
    Jaramillo-Polanco J; Liñán-Rico A; Espinosa-Luna R; Jiménez-Bremont JF; Montaño LM; Miranda-Morales M; Barajas-López C
    Biochem Biophys Res Commun; 2016 Aug; 477(1):54-61. PubMed ID: 27282483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists.
    Tian M; Abdelrahman A; Baqi Y; Fuentes E; Azazna D; Spanier C; Densborn S; Hinz S; Schmid R; Müller CE
    J Med Chem; 2020 Jun; 63(11):6164-6178. PubMed ID: 32345019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships of novel P2-receptor antagonists structurally related to Reactive Blue 2.
    Glänzel M; Bültmann R; Starke K; Frahm AW
    Eur J Med Chem; 2005 Dec; 40(12):1262-76. PubMed ID: 16153748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2X receptor chimeras highlight roles of the amino terminus to partial agonist efficacy, the carboxyl terminus to recovery from desensitization, and independent regulation of channel transitions.
    Allsopp RC; Farmer LK; Fryatt AG; Evans RJ
    J Biol Chem; 2013 Jul; 288(29):21412-21421. PubMed ID: 23740251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of P2X3 and P2X2/3 Receptors by Monoclonal Antibodies.
    Shcherbatko A; Foletti D; Poulsen K; Strop P; Zhu G; Hasa-Moreno A; Melton Witt J; Loo C; Krimm S; Pios A; Yu J; Brown C; Lee JK; Stroud R; Rajpal A; Shelton D
    J Biol Chem; 2016 Jun; 291(23):12254-70. PubMed ID: 27129281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists.
    Kai H; Horiguchi T; Kameyma T; Onodera N; Itoh N; Fujii Y; Ichihashi Y; Hirai K; Shintani T; Nakamura K; Minami K; Kasai E; Yoneda S; Murakami Y; Ogawa H; Sekimoto R; Shinohara S; Yoshida O; Kurose N
    Bioorg Med Chem Lett; 2021 Nov; 52():128384. PubMed ID: 34587541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.